Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA), the use of remdesivir in the treatment of COVID-19 has been supported in the UK by an Early Access to Medicines Scheme (EAMS), implemented from 26th May 2020, and subsequently by an interim clinical commissioning policy, which has been in place since 3 July.
The clinical commissioning policy (available as an attachment below) has now been updated to reflect the more positive position on remdesivir supply into the UK (via the European Union Joint Procurement Agreement arrangements) and to reflect the latest available evidence, including the results of the World Health Organization’s (WHO’s) Solidarity trial.